After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...